Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients

Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18.

Authors

Immacolata Attolico¹, Francesco Tarantini², Paola Carluccio¹, Claudia Pia Schifone², Mario Delia¹, Vito Pier Gagliardi¹, Tommasina Perrone¹, Francesco Gaudio¹, Chiara Longo¹, Annamaria Giordano¹, Nicola Sgherza¹, Paola Curci¹, Rita Rizzi², Alessandra Ricco¹, Antonella Russo Rossi¹, Francesco Albano², Angela Maria Vittoria Larocca³, Luigi Vimercati^{4

5}, Silvio Tafuri⁶, Pellegrino Musto^{1

2}

Affiliations

¹ Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy.
² Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy.
³ Hygiene Unit, AOUC Policlinico, Bari, Italy.
⁴ Interdisciplinary Department of Medicine, "Aldo Moro" University School of Medicine, Bari, Italy.
⁵ Occupational Medicine Unit, AOUC Policlinico, Bari, Italy.
⁶ Department of Biomedical Sciences and Human Oncology, 'Aldo Moro' University School of Medicine, Bari, Italy.

No abstract available

Keywords: seroconversion; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination; stem cell transplantation.

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Viral / blood
Antibodies, Viral / immunology
BNT162 Vaccine / pharmacology
BNT162 Vaccine / therapeutic use*
COVID-19 / blood
COVID-19 / immunology
COVID-19 / prevention & control*
Female
Hematopoietic Stem Cell Transplantation*
Humans
Immunogenicity, Vaccine
Immunoglobulin G / blood
Immunoglobulin G / immunology
Male
Middle Aged
SARS-CoV-2 / immunology*
Seroconversion
Young Adult

Substances

Antibodies, Viral
Immunoglobulin G
BNT162 Vaccine